# Immune Checkpoint Therapy With Nivolumab Esophageal Squamous Cell Carcinoma

> **NCT03278626** · PHASE1,PHASE2 · TERMINATED · sponsor: **NYU Langone Health** · enrollment: 12 (actual)

## Conditions studied

- Esophageal Squamous Cell Carcinoma

## Interventions

- **DRUG:** Nivolimumab+Carboplatin/paclitaxel+Radiation

## Key facts

- **NCT ID:** NCT03278626
- **Lead sponsor:** NYU Langone Health
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-06-27
- **Primary completion:** 2019-11-07
- **Final completion:** 2021-05-31
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** The study was stopped earlier than anticipated due to slow accrual
- **Last updated:** 2022-03-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03278626

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03278626, "Immune Checkpoint Therapy With Nivolumab Esophageal Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03278626. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*